USD 2.08
(-2.35%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -1.35 USD | -25.0% |
2022 | -1.08 USD | -200.0% |
2021 | -0.36 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | -0.50 USD | -19.05% |
2024 Q2 | -0.59 USD | -18.0% |
2023 Q2 | -0.32 USD | -18.52% |
2023 Q4 | -0.42 USD | -23.53% |
2023 FY | - USD | -25.0% |
2023 Q3 | -0.34 USD | -6.25% |
2023 Q1 | -0.27 USD | 10.0% |
2022 FY | - USD | -200.0% |
2022 Q4 | -0.30 USD | 0.0% |
2021 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
ADC Therapeutics SA | -2.94 USD | 54.082% |
Annovis Bio, Inc. | -6.23 USD | 78.331% |
Biohaven Pharmaceutical Holding Company Ltd. | -5.73 USD | 76.44% |
Ginkgo Bioworks Holdings, Inc. | -18.37 USD | 92.651% |
Nuvation Bio Inc. | -0.35 USD | -285.714% |
Nuvation Bio Inc. | -0.35 USD | -285.714% |
Arcus Biosciences, Inc. | -4.15 USD | 67.47% |
Zymeworks Inc. | -1.72 USD | 21.512% |